海利生物：9月12日召开董事会会议

Group 1 - The core point of the article is that Haili Biological announced a board meeting to discuss adjustments to the transaction price for a major asset purchase and the signing of a supplementary agreement [1] - For the fiscal year 2024, Haili Biological's revenue composition is as follows: medical devices account for 57.81%, veterinary biological products account for 42.19%, and other businesses account for 0.01% [1] - As of the report date, Haili Biological has a market capitalization of 4.6 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, which has been acknowledged by both Chinese and American officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]